ANVS Annovis BioWatchlist
About Annovis Bio Company
Annovis Bio, Inc. is a clinical stage drug platform company, which engages in the development of drugs which aims to treat neurodegenerative diseases such as Alzheimer's (AD) and Parkinson's (PD). Its lead product candidate, Buntanetap, is designed to address AD, PD, and potentially other chronic neurodegenerative diseases. Its product pipeline also includes ANVS405 and ANVS301, which focus on the treatment of traumatic brain injury, stroke, and advanced AD. The company was founded by Maria Luisa Maccecchini in May 2008 and is headquartered in Berwyn, PA.
Annovis Bio Announces Last Patient Last Visit in the Phase III Study of Buntanetap in Parkinson's Disease
BERWYN, Pa., Dec. 05, 2023 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE:ANVS), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases today announced last patient last visit in
Buy Rating Affirmed for Annovis Bio Amidst Strong Clinical Trial Progress and Robust Financial Position
HC Wainwright & Co. Reiterates Buy on Annovis Bio, Maintains $30 Price Target
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Annovis Bio with a Buy and maintains $30 price target.
Annovis said the board found no drug-related Serious Adverse Events, and an Adverse Event rate of less than 5%. The dropout rate for the study was 4.7%.
The company started the study in late March 2023.